210 related articles for article (PubMed ID: 23915145)
21. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
Chen S; Huang L; Chen CM; Shao ZM
Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
23. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Novelli F; Milella M; Melucci E; Di Benedetto A; Sperduti I; Perrone-Donnorso R; Perracchio L; Venturo I; Nisticò C; Fabi A; Buglioni S; Natali PG; Mottolese M
Breast Cancer Res; 2008; 10(5):R74. PubMed ID: 18771580
[TBL] [Abstract][Full Text] [Related]
24. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
Kucuk U; Bayol U; Pala EE; Cumurcu S
Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.
Kakudji BK; Mwila PK; Burger JR; du Plessis JM; Naidu K
Pan Afr Med J; 2021; 38():85. PubMed ID: 33889251
[TBL] [Abstract][Full Text] [Related]
26. Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity.
Davis MB; Liu X; Wang S; Reeves J; Khramtsov A; Huo D; Olopade OI
Mol Cancer; 2013 May; 12(1):40. PubMed ID: 23663560
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.
Erdem O; Dursun A; Coşkun U; Günel N
Tumori; 2005; 91(1):46-52. PubMed ID: 15850004
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer subtypes and the risk of local and regional relapse.
Voduc KD; Cheang MC; Tyldesley S; Gelmon K; Nielsen TO; Kennecke H
J Clin Oncol; 2010 Apr; 28(10):1684-91. PubMed ID: 20194857
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
30. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
31. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
[TBL] [Abstract][Full Text] [Related]
32. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
33. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
36. TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.
Bertozzi S; Londero AP; Viola L; Orsaria M; Bulfoni M; Marzinotto S; Corradetti B; Baccarani U; Cesselli D; Cedolini C; Mariuzzi L
BMC Cancer; 2021 Oct; 21(1):1118. PubMed ID: 34663249
[TBL] [Abstract][Full Text] [Related]
37. In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Gwe Ahn S; Ah Lee S; Woo Lee H; Min Lee H; Jeong J
Jpn J Clin Oncol; 2014 Jul; 44(7):624-31. PubMed ID: 24803548
[TBL] [Abstract][Full Text] [Related]
38. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
39. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
40. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]